Athersys, Inc. (ATHX): Price and Financial Metrics
ATHX Stock Summary
- The ratio of debt to operating expenses for Athersys Inc is higher than it is for about just 0.48% of US stocks.
- ATHX's price/sales ratio is 869.53; that's higher than the P/S ratio of 99.14% of US stocks.
- Revenue growth over the past 12 months for Athersys Inc comes in at -93.34%, a number that bests just 1.2% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Athersys Inc are CRNX, FIXX, BBIO, INO, and NTLA.
- ATHX's SEC filings can be seen here. And to visit Athersys Inc's official web site, go to www.athersys.com.
ATHX Stock Price Chart Interactive Chart >
ATHX Price/Volume Stats
| Current price | $1.88 | 52-week high | $4.38 |
| Prev. close | $2.01 | 52-week low | $1.13 |
| Day low | $1.88 | Volume | 3,547,155 |
| Day high | $2.08 | Avg. volume | 3,343,521 |
| 50-day MA | $2.15 | Dividend yield | N/A |
| 200-day MA | $2.25 | Market Cap | 371.68M |
Athersys, Inc. (ATHX) Company Bio
Athersys, Inc. focuses on the research and development activities in the field of regenerative medicine. The company was founded in 1995 and is based in Cleveland, Ohio.
Latest ATHX News From Around the Web
Below are the latest news stories about Athersys Inc that investors may wish to consider to help them evaluate ATHX as an investment opportunity.
Athersys to Host Year-End 2020 Financial Results CallAthersys will host the year-end 2020 financial results call on March 25th. |
Athersys Announces CEO TransitionCLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys |
Athersys Announces Cooperation Agreement With HEALIOS K.K.Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan. |
Longeveron Seeks $25 Million IPO For Anti-Aging EffortsQuick Take Longeveron (LGVN) has filed to raise $25 million in an IPO of its Class A common stock, according to an S-1 registration statement. The firm is a clinical stage firm is developing treatment candidates for various aging conditions. LGVN is thinly capitalized and pursuing an ultra-high-risk effort for... |
Update On Athersys - Trying To Read Between The LinesThere is a very fascinating confluence of circumstances that have come together over the last few months surrounding the shares of stem cell therapeutics company, Athersys Inc. (ATHX). I’ve held the shares for longer than I want to admit and I recently was informed that, in the new language of... |
ATHX Price Returns
| 1-mo | -22.95% |
| 3-mo | 9.30% |
| 6-mo | -4.57% |
| 1-year | 54.10% |
| 3-year | 38.24% |
| 5-year | 5.62% |
| YTD | 7.43% |
| 2020 | 42.28% |
| 2019 | -14.58% |
| 2018 | -20.44% |
| 2017 | 18.30% |
| 2016 | 48.54% |
Continue Researching ATHX
Here are a few links from around the web to help you further your research on Athersys Inc's stock as an investment opportunity:Athersys Inc (ATHX) Stock Price | Nasdaq
Athersys Inc (ATHX) Stock Quote, History and News - Yahoo Finance
Athersys Inc (ATHX) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...